A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
Clinical trial NCT05762393 · COMPLETED
Trial details
- NCT number
- NCT05762393
- Sponsor
- International Vaccine Institute
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-17
- Primary completion
- 2025-05-19
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.